INTRACEF 250 mg, 750 mg and 1,5 g sterile powder for injection.
Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Patient Information leaflet
(PIL)
26-04-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Available from:
Lennon
Patient Information leaflet
INDICATIONS [/za_1307.html#1]
[/za_1307.html#1] [/za_1307.html#1]
CONTRA-INDICATIONS [/za_1307.html#1]
[/za_1307.html#1]
DOSAGE [/za_1307.html#1]
[/za_1307.html#1]
SIDE-EFFECTS [/za_1307.html#1]
[/za_1307.html#1] [/za_1307.html#1]
PREGNANCY [/za_1307.html#1]
[/za_1307.html#1]
OVERDOSE [/za_1307.html#1]
IDENTIFICATION [/za_1307.html#1]
[/za_1307.html#1] PATIENT INFORMATION
INTRACEF 250 MG, 750 MG AND 1,5 G STERILE POWDER FOR
INJECTION.
SCHEDULING STATUS:
S4
PROPRIETARY NAME
(and dosage form):
INTRACEF 250 MG, 750 MG AND 1,5 G STERILE POWDER FOR INJECTION.
COMPOSITION:
Vials containing 250 mg, 750 mg and 1,5 g
CEFUROXIME
as cefuroxime sodium.
PHARMACOLOGICAL CLASSIFICATION:
A 20.1.1 - Antimicrobial agents: Broad and medium spectrum antibiotics.
PHARMACOLOGICAL ACTION:
Cefuroxime is a bactericidal semi-synthetic cephalosporin antibiotic which is resistant to most ß-lactamases and is
active against a wide range of Gram-positive and Gram-negative organisms. Peak serum levels of cefuroxime are
reached within 30 to 45 minutes after intramuscular administration. The serum half-life after either intramuscular or
intravenous injection is approximately 70 minutes. Concurrent administration of probenecid produces an elevated peak
serum level and restricts the excretion of the antibiotic. There is almost complete recovery of unchanged cefuroxime in
the urine within 24 hours of administration the major part being eliminated within the first 6 hours. The tubular excretion
component of renal clearance of cefuroxime is of the order of 50%.
INDICATIONS:
Cefuroxime is indicated for the treatment of the following infections when caused by susceptible strains of the
designated micro-organisms:
Respiratory tract infections
Ear, nose and throat infections
Urinary tract infections
Bone
Read the complete document
